Moran Lisa J, Hutchison Samantha K, Norman Robert J, Teede Helena J
The Jean Hailes Clinical Research Unit, School of Public Health and Preventive Medicine, Monash University, Locked bag 29, Monash Medical Centre, Clayton Road, Clayton Road, Clayton, Victoria, Australia, 3168.
Cochrane Database Syst Rev. 2011 Feb 16(2):CD007506. doi: 10.1002/14651858.CD007506.pub2.
Polycystic ovary syndrome (PCOS) affects 4% to 18% of reproductive-aged women and is associated with reproductive, metabolic and psychological dysfunction. Obesity worsens the presentation of PCOS and weight management (weight loss, maintenance or prevention of excess weight gain) is proposed as an initial treatment strategy, best achieved through lifestyle changes incorporating diet, exercise and behavioural interventions.
To assess the effectiveness of lifestyle treatment in improving reproductive, anthropometric (weight and body composition), metabolic and quality of life factors in PCOS.
Electronic databases (Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE, PsycINFO, CINAHL, AMED), controlled trials register, conference abstracts, relevant journals, reference lists of relevant papers and reviews and grey literature databases, with no language restrictions applied.
Randomised controlled trials comparing lifestyle treatment (diet, exercise, behavioural or combined treatments) to minimal or no treatment in women with PCOS.
Two authors independently selected trials, assessed methodological quality and risk of bias and extracted data.
Six studies were included. Three studies compared physical activity to minimal dietary and behavioural advice or no advice. Three studies compared combined dietary, exercise and behavioural interventions to minimal intervention. There were no studies assessing fertility primary outcomes and no data for meta-analysis on ovulation or menstrual regularity. For secondary outcomes, lifestyle intervention provided benefits when compared to minimal treatment for endpoint values for total testosterone (mean difference (MD) -0.27 nmol/L, 95% confidence interval (CI) -0.46 to -0.09, P = 0.004), hirsutism by the Ferriman-Gallwey score (MD -1.19, 95% CI -2.35 to -0.03, P = 0.04), weight (MD -3.47 kg, 95% CI -4.94 to -2.00, P < 0.00001), waist circumference (MD -1.95 cm, 95% CI -3.34 to -0.57, P = 0.006), waist to hip ratio (MD -0.04, 95% CI -0.07 to -0.00, P = 0.02), fasting insulin (MD -2.02 µU/mL, 95% CI -3.28 to -0.77, P = 0.002) and oral glucose tolerance test insulin (standardised mean difference -1.32, 95% CI -1.73 to -0.92, P < 0.00001) and per cent weight change (MD -7.00%, 95% CI -10.1 to -3.90, P < 0.00001). There was no evidence of effect of lifestyle for body mass index, free androgen index, sex hormone binding globulin, glucose or lipids; and no data for quality of life, patient satisfaction or acne.
AUTHORS' CONCLUSIONS: Lifestyle intervention improves body composition, hyperandrogenism (high male hormones and clinical effects) and insulin resistance in women with PCOS. There was no evidence of effect for lifestyle intervention on improving glucose tolerance or lipid profiles and no literature assessing clinical reproductive outcomes, quality of life and treatment satisfaction.
多囊卵巢综合征(PCOS)影响4%至18%的育龄妇女,与生殖、代谢及心理功能障碍相关。肥胖会使PCOS的症状加重,体重管理(减重、维持体重或预防体重过度增加)被提议作为初始治疗策略,最佳方式是通过饮食、运动及行为干预等生活方式的改变来实现。
评估生活方式治疗对改善PCOS患者生殖、人体测量学指标(体重和身体成分)、代谢及生活质量因素的有效性。
电子数据库(Cochrane对照试验中心注册库(CENTRAL)(Cochrane图书馆)、MEDLINE、EMBASE、PsycINFO、CINAHL、AMED)、对照试验注册库、会议摘要、相关期刊、相关论文及综述的参考文献列表以及灰色文献数据库,无语言限制。
比较生活方式治疗(饮食、运动、行为或联合治疗)与PCOS女性最少治疗或不治疗的随机对照试验。
两位作者独立选择试验、评估方法学质量和偏倚风险并提取数据。
纳入六项研究。三项研究将体育活动与最少饮食及行为建议或无建议进行比较。三项研究将饮食、运动及行为联合干预与最少干预进行比较。没有评估生育主要结局的研究,也没有关于排卵或月经规律的荟萃分析数据。对于次要结局,与最少治疗相比,生活方式干预在总睾酮终点值(平均差(MD)-0.27 nmol/L,95%置信区间(CI)-0.46至-0.09,P = 0.004)、费里曼-盖尔韦毛发评分法评估的多毛症(MD -1.19,95% CI -2.35至-0.03,P = 0.04)、体重(MD -3.47 kg,95% CI -4.94至-2.00,P < 0.00001)、腰围(MD -1.95 cm,95% CI -3.34至-0.57,P = 0.006)、腰臀比(MD -0.04,95% CI -0.07至-0.00,P = 0.02)、空腹胰岛素(MD -2.02 µU/mL,95% CI -3.28至-0.77,P = 0.002)和口服葡萄糖耐量试验胰岛素(标准化平均差-1.32,95% CI -1.73至-0.92,P < 0.00001)以及体重变化百分比(MD -7.00%,95% CI -10.1至-3.90,P < 0.00001)方面有获益。没有证据表明生活方式对体重指数、游离雄激素指数、性激素结合球蛋白、血糖或血脂有影响;也没有关于生活质量、患者满意度或痤疮的数据。
生活方式干预可改善PCOS女性的身体成分、高雄激素血症(高雄性激素及临床效应)和胰岛素抵抗。没有证据表明生活方式干预对改善葡萄糖耐量或血脂水平有效果,也没有评估临床生殖结局、生活质量和治疗满意度的文献。